Christopher A Bagby, MD | |
2102 Baptiste Dr Ste E, Paola, KS 66071-1314 | |
(913) 557-3800 | |
(913) 557-5989 |
Full Name | Christopher A Bagby |
---|---|
Gender | Male |
Speciality | Orthopedic Surgery |
Experience | 34 Years |
Location | 2102 Baptiste Dr Ste E, Paola, Kansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528152501 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | 04-26156 (Kansas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Miami County Medical Center | Paola, KS | Hospital |
Olathe Medical Center | Olathe, KS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Olathe Health Physicians Inc | 7618881905 | 200 |
Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.
IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.
A new Perspective article in Nature Reviews Cancer discusses reasons for the moderate progress and describes remedies designed to facilitate the transition to the clinic.
Researchers at UPF, the National Centre for Cardiovascular Research, ICREA and Ciberned have identified a physiological mechanism that maintains the regenerative capacity of muscle stem cells, and surprisingly resists the passage of time far more than expected, until geriatric age.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
› Verified 6 days ago
Entity Name | Olathe Health Physicians Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1598784639 PECOS PAC ID: 7618881905 Enrollment ID: O20031119000719 |
News Archive
Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.
IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.
A new Perspective article in Nature Reviews Cancer discusses reasons for the moderate progress and describes remedies designed to facilitate the transition to the clinic.
Researchers at UPF, the National Centre for Cardiovascular Research, ICREA and Ciberned have identified a physiological mechanism that maintains the regenerative capacity of muscle stem cells, and surprisingly resists the passage of time far more than expected, until geriatric age.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
› Verified 6 days ago
Entity Name | Kansas University Physicians, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.
IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.
A new Perspective article in Nature Reviews Cancer discusses reasons for the moderate progress and describes remedies designed to facilitate the transition to the clinic.
Researchers at UPF, the National Centre for Cardiovascular Research, ICREA and Ciberned have identified a physiological mechanism that maintains the regenerative capacity of muscle stem cells, and surprisingly resists the passage of time far more than expected, until geriatric age.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
› Verified 6 days ago
Entity Name | Saint Lukes Physician Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093263717 PECOS PAC ID: 3577476894 Enrollment ID: O20050302000266 |
News Archive
Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.
IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.
A new Perspective article in Nature Reviews Cancer discusses reasons for the moderate progress and describes remedies designed to facilitate the transition to the clinic.
Researchers at UPF, the National Centre for Cardiovascular Research, ICREA and Ciberned have identified a physiological mechanism that maintains the regenerative capacity of muscle stem cells, and surprisingly resists the passage of time far more than expected, until geriatric age.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Christopher A Bagby, MD 2102 Baptiste Dr Ste E, Paola, KS 66071-1314 Ph: (913) 557-3800 | Christopher A Bagby, MD 2102 Baptiste Dr Ste E, Paola, KS 66071-1314 Ph: (913) 557-3800 |
News Archive
Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans. These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.
IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.
A new Perspective article in Nature Reviews Cancer discusses reasons for the moderate progress and describes remedies designed to facilitate the transition to the clinic.
Researchers at UPF, the National Centre for Cardiovascular Research, ICREA and Ciberned have identified a physiological mechanism that maintains the regenerative capacity of muscle stem cells, and surprisingly resists the passage of time far more than expected, until geriatric age.
Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.
› Verified 6 days ago